AKT1 and Parkinson disease: This evidence has been supported by several studies on pharmacological treatment, such as exenatide and rotigotine, to improve PD via the activation of PI3K/Akt/mTOR pathway (Oster et al., 2014; Hauser et al., 2016; Athauda et al., 2019).